分泌生长激素的垂体癌:1例报告及文献复习

IF 1.6 4区医学 Q4 CELL BIOLOGY

Growth Hormone & Igf Research Pub Date : 2021-10-01 DOI:10.1016/j.ghir.2021.101430

Shivani Vekaria , Fei Chen , Elcin Zan , Christopher William , Chandra Sen , Richard Lebowitz , David Zagzag , Floyd A. Warren , Tamar C. Brandler , Nidhi Agrawal

{"title":"分泌生长激素的垂体癌:1例报告及文献复习","authors":"Shivani Vekaria , Fei Chen , Elcin Zan , Christopher William , Chandra Sen , Richard Lebowitz , David Zagzag , Floyd A. Warren , Tamar C. Brandler , Nidhi Agrawal","doi":"10.1016/j.ghir.2021.101430","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Pituitary carcinoma is a rare tumor, defined as a tumor of adenohypophyseal cells with systemic or craniospinal metastasis. We present a case of a growth hormone (GH)-secreting pituitary carcinoma with a review of literature to better characterize this disease.</p></div><div><h3>Design</h3><p>Case report and literature review of 25 cases of GH-secreting pituitary carcinomas</p></div><div><h3>Results</h3><p>The age of diagnosis of GH-secreting carcinomas ranged 24–69 years old with a mean age of 44.4 with 52% of cases present in females. Mean latency period between diagnosis of acromegaly and transition to pituitary carcinoma was 11.4 years with mean survival being 3.4 years.</p></div><div><h3>Conclusion</h3><p><span>Growth hormone (GH)-secreting pituitary carcinomas are rare and hard to distinguish from aggressive pituitary adenomas<span><span>. From review of literature, treatment options include </span>debulking surgery, radiotherapy, or chemotherapy with dismal outcomes. There are no diagnostic markers or features which can predict metastatic progression of these tumors. Future studies with genomic landscapes and relevant tumor markers are needed to identify </span></span>pituitary tumors most likely to metastasize.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101430"},"PeriodicalIF":1.6000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Growth hormone secreting pituitary carcinomas: Case report and review of literature\",\"authors\":\"Shivani Vekaria , Fei Chen , Elcin Zan , Christopher William , Chandra Sen , Richard Lebowitz , David Zagzag , Floyd A. Warren , Tamar C. Brandler , Nidhi Agrawal\",\"doi\":\"10.1016/j.ghir.2021.101430\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Pituitary carcinoma is a rare tumor, defined as a tumor of adenohypophyseal cells with systemic or craniospinal metastasis. We present a case of a growth hormone (GH)-secreting pituitary carcinoma with a review of literature to better characterize this disease.</p></div><div><h3>Design</h3><p>Case report and literature review of 25 cases of GH-secreting pituitary carcinomas</p></div><div><h3>Results</h3><p>The age of diagnosis of GH-secreting carcinomas ranged 24–69 years old with a mean age of 44.4 with 52% of cases present in females. Mean latency period between diagnosis of acromegaly and transition to pituitary carcinoma was 11.4 years with mean survival being 3.4 years.</p></div><div><h3>Conclusion</h3><p><span>Growth hormone (GH)-secreting pituitary carcinomas are rare and hard to distinguish from aggressive pituitary adenomas<span><span>. From review of literature, treatment options include </span>debulking surgery, radiotherapy, or chemotherapy with dismal outcomes. There are no diagnostic markers or features which can predict metastatic progression of these tumors. Future studies with genomic landscapes and relevant tumor markers are needed to identify </span></span>pituitary tumors most likely to metastasize.</p></div>\",\"PeriodicalId\":12803,\"journal\":{\"name\":\"Growth Hormone & Igf Research\",\"volume\":\"60 \",\"pages\":\"Article 101430\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Growth Hormone & Igf Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1096637421000538\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Growth Hormone & Igf Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096637421000538","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 3

摘要

目的垂体癌是一种少见的肿瘤，定义为腺垂体细胞的肿瘤伴全身或颅脊髓转移。我们提出一个病例生长激素(GH)分泌垂体癌与文献回顾，以更好地表征这种疾病。25例垂体gh分泌癌病例报告及文献复习结果gh分泌癌的诊断年龄为24 ~ 69岁，平均年龄44.4岁，女性占52%。从诊断肢端肥大症到转变为垂体癌的平均潜伏期为11.4年，平均生存期为3.4年。结论垂体生长激素(GH)分泌型垂体腺瘤罕见，难以与侵袭性垂体腺瘤鉴别。从文献综述来看，治疗选择包括减脂手术、放疗或化疗，但结果不佳。没有诊断标记物或特征可以预测这些肿瘤的转移进展。未来需要通过基因组图谱和相关肿瘤标志物的研究来确定最有可能转移的垂体肿瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Growth hormone secreting pituitary carcinomas: Case report and review of literature

Objective

Pituitary carcinoma is a rare tumor, defined as a tumor of adenohypophyseal cells with systemic or craniospinal metastasis. We present a case of a growth hormone (GH)-secreting pituitary carcinoma with a review of literature to better characterize this disease.

Design

Case report and literature review of 25 cases of GH-secreting pituitary carcinomas

Results

The age of diagnosis of GH-secreting carcinomas ranged 24–69 years old with a mean age of 44.4 with 52% of cases present in females. Mean latency period between diagnosis of acromegaly and transition to pituitary carcinoma was 11.4 years with mean survival being 3.4 years.

Conclusion

Growth hormone (GH)-secreting pituitary carcinomas are rare and hard to distinguish from aggressive pituitary adenomas. From review of literature, treatment options include debulking surgery, radiotherapy, or chemotherapy with dismal outcomes. There are no diagnostic markers or features which can predict metastatic progression of these tumors. Future studies with genomic landscapes and relevant tumor markers are needed to identify pituitary tumors most likely to metastasize.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Growth Hormone & Igf Research 医学-内分泌学与代谢

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

57 days

期刊介绍： Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.